UNSPSC 51286602: Ftivazide

This classification denotes an antitubercular agent with the molecular formula C14H13N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40Q4C3O4V0, chemically known as isonicotinic acid, vanillylidenehydrazide but more generally known as ftivazide, which bears US NIH Compound Identifier 5355297. European Medicines Agency schedules Ftivazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07821MIG.

The term FTIVAZIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). FTIVAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1=C/C(=C/NNC(=O)C2CCNCC2)C=CC1=O)C.

UNSPSC 51286602 Ftivazide, a Commodity code, does not align with the recent state and local solicitations tagged under it. The code nominally describes a specific pharmaceutical compound (ftivazide), but the recent opportunities on record show state and local governments procuring naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, medical and first aid supplies for emergency response, and establishing direct-to-manufacturer prescription programs—none of which are ftivazide-specific products. The mismatch suggests either a cataloging error in the underlying procurement database or that ftivazide is being procured as part of broader pharmaceutical procurement categories that state and local agencies tag with this code. State and local governments issuing under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local members across multiple jurisdictions including Oregon).

Recent activity appears across Florida, Texas, Minnesota, and participating states within cooperative purchasing vehicles, with no clear geographic concentration. Representative recent opportunities include Seminole County's IFB for naloxone and safe drug deactivation systems (posted June 30, 2026, due July 26, 2023—note a date discrepancy in the source), the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000.00 (due March 13, 2026, designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount), Minnesota's MMCAP RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026), and the Texas HHS Commission's RFI on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program (posted April 3, 2026). The lack of ftivazide-specific solicitations in the recent record suggests this code warrants clarification before resource allocation.